Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR114: a multi-targeted kinase inhibitor for solid tumors”（2018/12/13）
Title: NHRI technology, “DBPR114: a multi-targeted kinase inhibitor for solid tumors” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR114 is a novel small molecule multi-target kinase inhibitor. Multi-target drugs can more effectively inhibit cancer cell proliferation, overcome drug resistance, and show better and broader anti-cancer effects. DBPR114 significantly shrank tumor …
